Abstract:Objective: To investigate the efficacy of intratumoral injection of paclitaxel-loaded poly (lactic-co-glycolic acid) (PLGA) microspheres on Hep-2 laryngeal squamous cell xenografts in nude mice. Methods: The solid tumor model bearing Hep-2 laryngeal squamous cell carcinoma was established in BALB/c nude mice. The model group was given with different therapies. The tumor size and tumor weight were recorded in all of the experimental groups. The tumor inhibition rate (IR) and tumor volume tripling time (TT) were calculated. The counts of microvessel density (MVD), expressions of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in xenografts were examined by Envision™ immunohistological method. Results: Twenty-one days after treatment, the tumor size and tumor weight of the paclitaxel-treated groups were significantly decreased (P < 0.05) and the TTs were significantly prolonged (P < 0.01) compared with the saline control group. The TT of the group receiving intratumoral injection of paclitaxel PLGA microspheres at a low dose was significantly longer compared with the group receiving intratumoral (i. t.) or intraperitoneal (i. p.) injection of paclitaxel (P <0.05). The TT of the group receiving intratumoral injection of paclitaxel microspheres at a high dose was significantly increased compared with the other paclitaxel-treated groups (P < 0.01). The tumor inhibition rates of paclitaxel intraperitoneal or intratumoral injection groups were 35.99% and 39.37%, respectively; and they were 47.83% and 59.90% for paclitaxel microsphere intratumoral injection groups at low and high doses, respectively. PLGA blank microspheres had no effect on the tumor growth. No significant toxic reactions were observed in the experiment. The counts of MVD and immunoreactivity of bFGF and VEGF in the paclitaxel-treated groups were significantly decreased compared with the saline control group (P < 0.05). The intratumoral injection of paclitaxel microspheres markedly reduced bFGF level and showed stronger anti-angiogenic activity in comparison with i. p. and i. t. administration of paclitaxel injection (P < 0.01). Conclusion: Direct administration of polymeric drug control release system into local tumor bodies had a foreground for the treatment of laryngeal squamous cell carcinoma.

Effective antitumor activity of paclitaxel-loaded poly (ϵ-caprolactone)/pluronic F68 nanoparticles after intratumoral delivery into the murine breast cancer model

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.

Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models

The Inhibitory Effect of Paclitaxel Nanoparticles on Ovarian Cancer Xenografts and Lymphatic Targeting

Paclitaxel-loaded Poly(n-Vinylpyrrolidone)-b-poly(ε-caprolactone) Nanoparticles: Preparation and Antitumor Activity in Vivo

Experimental study on effects of intratumoral injection of paclitaxel-loaded poly (lactic-co-glycolic acid) micro-spheres on Hep-2 laryngeal squamous cell carcinoma xenografts in nude mice

Paclitaxel Nanoparticle Inhibits Growth of Ovarian Cancer Xenografts and Enhances Lymphatic Targeting.

Preparation of paclitaxel loaded PLGA microspheres and its efficacy in Hep-2 laryngeal squamous cell carcinoma-bearing nude mice

Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer

Antitumor Efficiency of D-α-Tocopheryl Polyethylene Glycol 1000 Succinate-b-Poly(ε-caprolactone-<I>ran</I>-lactide) Nanoparticle-Based Delivery of Docetaxel in Mice Bearing Cervical Cancer

The Antitumor Efficacy of Functional Paclitaxel Nanomicelles in Treating Resistant Breast Cancers by Oral Delivery

Antitumor efficiency of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer.

The Potential of Pluronic Polymeric Micelles Encapsulated with Paclitaxel for the Treatment of Melanoma Using Subcutaneous and Pulmonary Metastatic Mice Models

Facile fabrication of TPGS-PCL polymeric nanoparticles for paclitaxel delivery to breast cancer: investigation of antiproliferation and apoptosis induction

Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol).

Primary study on the treatment of rat ovarian carcinoma via the intraperitoneal administration of paclitaxel nanoparticles

Enhanced Paclitaxel Efficacy to Suppress Triple-Negative Breast Cancer Progression Using Metronomic Chemotherapy with a Controlled Release System of Electrospun Poly-d-l-Lactide-Co-Glycolide (PLGA) Nanofibers

A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment